ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 30

A Mouse Myeloid Precursor with Osteoclastogenic Function in Vivo

Julia F. Charles1, Erene Niemi2, Mary C. Nakamura3 and Antonios O. Aliprantis4, 1Rheumatology, Allergy and Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Medicine, University of California, San Francisco; VA Medical Center, San Francisco, 3Arthritis/Rheumatology 111-R, SFVAMC/UCSF, San Francisco, CA, 4Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Bone marrow and osteoclasts

  • Tweet
  • Email
  • Print
Session Information

Title: Biology and Pathology of Bone and Joint

Session Type: Abstract Submissions (ACR)

Background/Purpose: Osteoporosis and peri-articular erosions in patients with inflammatory arthritis are characterized by increased osteoclast resorptive activity.  Although a great deal is known about how osteoclasts differentiate from precursors and resorb bone, the identity of the osteoclast precursor (OCP) in vivo remains elusive. Using ex vivo assays of osteoclast differentiation, we previously demonstrated that the majority of bone marrow OCP activity resides in the CD11b-/lo Ly6Chi cKit+ population. 

Methods: Fluorescence activated cell sorting was used to examine multiple markers on OCP and to isolate OCP from mT/mG cathepsin K cre+ mice.  mT/mg cathepsin K cre donor OCP are RFP+ at baseline and GFP+ in the presence of cre recombinase in mature osteoclasts.  Donor OCP were transfered by intramedulary injection into NFATc1 fl/fl Mx1-Cre osteoclast deficient mice and donor derived osteoclasts were detected by IHC.  Alternatively, donor OCP were injected intravenously into C57BL/6 mice 24 hrs after calvarial injection of 20mg/kg LPS.  Ex vivo osteoclast, dendritic cell, and macrophage cutures and assays were performed according to standard techniques.

Results: Here we show that the CD11b-/lo Ly6Chi cKit+ OCP population can be distinguished from the recently described quiescent osteoclast precursor by their proliferative capacity and absence of RANK (receptor activator of nuclear factor kappa B) expression. Similar to other myeloid precursors, OCP retain plasticity in vitro, differentiating into dendritic cells or phagocytic macrophages when stimulated with GM-CSF or MCSF, respectively. Adoptive transfer of this OCP population into osteoclast deficient hosts resulted in the formation of donor-derived mature, multinucleated TRAP+osteoclasts in vivo.  By combining adoptive transfer with an inflammatory stimulus (lipopolysaccharide injection into the calvaria) we further show that these OCP can be recruited to and differentiate at sites of inflammatory osteolysis.  Thus, we demonstrate that bone marrow OCP can migrate to stimuli known to promote osteoclastic bone resorption.

Conclusion: We demonstrate that the CD11b-/lo Ly6Chi cKit+ bone marrow population is a bona fide OCP.  Furthermore, this work provides a model system to identify the chemokine and cytokine requirements for recruiting osteoclasts to sites of inflammatory bone loss in diseases such as rheumatoid and psoriatic arthritis.


Disclosure:

J. F. Charles,
None;

E. Niemi,
None;

M. C. Nakamura,
None;

A. O. Aliprantis,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-mouse-myeloid-precursor-with-osteoclastogenic-function-in-vivo/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology